| Id: | acc5049 |
| Group: | 2sens |
| Protein: | VASP |
| Gene Symbol: | Vasp |
| Protein Id: | P70460 |
| Protein Name: | VASP_MOUSE |
| PTM: | phosphorylation |
| Site: | Ser239 |
| Site Sequence: | KLRKVSKQEEASGGPLAPKAE |
| Disease Category: | Endocrine and metabolic diseases |
| Disease: | Diabetes Mellitus |
| Disease Subtype: | proliferative vascular diseases |
| Disease Cellline: | |
| Disease Info: | |
| Drug: | PKG-OE |
| Drug Info: | No information available to describe the drug. |
| Effect: | modulate |
| Effect Info: | "Transfecting cells with the expression vector PKG - CD of the catalytic domain of PKG - I can restore the decrease in PKG activity in VSMCs mediated by high glucose and the decrease in VASP phosphorylation levels caused by high - glucose treatment, which may contribute to the prevention of abnormal proliferation of VSMCs in diabetic patients." |
| Note: | Non-conventional drugs |
| Score: | 3.0 |
| Pubmed(PMID): | 19717728 |
| Sentence Index: | 19717728_5-6 |
| Sentence: | "Our data demonstrated that high glucose exposure stimulated VSMC proliferation and G1 to S phase progression of the cell cycle, which was inhibited by restoration of PKG activity. Expression of constitutively active PKG inhibited G1 phase exit in VSMCs under high glucose conditions, which was accompanied by an inhibition of retinoblastoma protein (Rb) phosphorylation (a key switch for G1 to S phase cell cycle progression)." |
Sequence & Structure:
MSETVICSSRATVMLYDDSNKRWLPAGTGPQAFSRVQIYHNPTANSFRVVGRKMQPDQQVVINCAIIRGVKYNQATPIFHQWRDARQVWGLNFGSKEDAIQFATGMANALEALEGGGPPPAPAPPAWSAQNGPSPEELEQQKRQPEHMERRVSNAGGPPAPPAGGPPPPPGPPPPPGPPPPPGLPSSGVSGAGHGAGAAPPPAPPLPTAQGPNSGGSGAPGLAAAIAGAKLRKVSKQEEASGGPLAPKAENSRSTGGGLMEEMNAMLARRRKATQVGEKPPKDESASEESEARLPAQSEPVRRPWEKNSTTLPRMKSSSSVTTSEAHPSTPCSSDDSDLERVKQELLEEVRKELQKMKEEIIEVFVQELRKRGSP
Select PDB:
No data.
Protein Tractability:
source: Open TargetsNo data.
PTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| S | 239 | U | Marfan syndrome | Phosphorylation | 33976159 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
